You prove my point in another post of mine @Mom88. Biotechs have been sold down horrendously over the last few years and will always be able to raise money if they have viable IP. I can see Osteopore is just one of many biotechs which may rise substially in the future once their products are approved.
Ann: Prospectus for Renounceable Rights Issue, page-34
Add OSX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.319M | |||
| Open | High | Low | Value | Volume |
| 6.5¢ | 7.3¢ | 6.3¢ | $366.9K | 5.402M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90000 | 6.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.5¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.27pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.6¢ |
Change
0.000 ( 3.94 %) |
||||
| Open | High | Low | Volume | ||
| 6.5¢ | 7.4¢ | 6.2¢ | 1784134 | ||
| Last updated 15.57pm 17/06/2024 ? | |||||
| OSX (ASX) Chart |
